



DOCUMENT VERSION: CI24-05.01

Introduction

As explained in the Rules of Participation, Project Leaders may submit their Project to Stage 1, 2 or 3 of the Programme. To complete the application, candidates should fill in the block 0, which is common to the three stages of the programme. Within this block 0, applicants will find a guideline to help them choose the Stage of the Programme their project fits best. In the question "Please, choose the scenario that better matches the current status of your project" they should select Scenario 1, if they wish to apply for Stage 1; Scenario 2 to apply for Stage 2, and Scenario 3 to apply for Stage 3. After this selection, a different form will appear depending upon the selected Stage.

Common to all stages


Block 0 – General data and proposal information

APPLICATION DETAILS

- » Call name:
- » Application number:
- » Proposal Title: 100 characters, mandatory.
- » Proposal Description: 200 characters, mandatory.
- » Proposal Acronym: 20 characters, mandatory.
- » Project Leader:
- » Host Organization:
- » Faculty or Research Center (if applicable): 100 characters, optional.
- » Is the Project Leader the principal investigator of the research group developing the Asset? **Yes/No. Mandatory.**

If user answers No to the previous question:

Please identify the research group developing the Asset/s in the Host Organization (i.e., by means of the Principal Investigator in charge and, if possible, the lab name): **100 characters, mandatory.**



CLASSIFICATION OF THE APPLICATION

If * is shown, the answers to that question are locked from modification when changing status from Pre-draft to Draft. User must return to Pre-draft status to modify these fields.

Select the business area of your project, mandatory.

| | Therapeutics |
|--|-----------------|
| | Diagnostics |
| | Medical Devices |
| | Digital Health |


Select the scientific area(s) of your project, mandatory.

| Molecular and Structural Biology and Biochemistry |
|--|
| Genetics, Genomics, Bioinformatics and Systems Biology |
| Cellular and Developmental Biology |
| Physiology, Pathophysiology and Endocrinology |
| Neurosciences and Neural Disorders |
| Immunity and Infection |
| Diagnostic Tools, Therapies and Public Health |
| Applied life Sciences and Non-Medical Biotechnology |


Select the relevant subareas of your project, it is **mandatory** to select between 2 and 4.

| 1 | Molecular and Structural Biology and Biochemistry |
|------|---|
| 1_1 | Molecular interactions |
| 1_2 | General biochemistry and metabolism |
| 1_3 | DNA synthesis, modification, repair, recombination and degradation |
| 1_4 | RNA synthesis, processing, modification and degradation |
| 1_5 | Protein synthesis, modification and turnover |
| 1_6 | Lipid synthesis, modification and turnover |
| 1_7 | Carbohydrate synthesis, modification and turnover |
| 1_8 | Biophysics (e.g. transport mechanisms, bioenergetics, fluorescence) |
| 1_9 | Structural biology (crystallography and EM) |
| 1_10 | Structural biology (NMR) |
| 1_11 | Biochemistry and molecular mechanisms of signal transduction |

| 2_1 Genetics, Genomics, Bioinformatics and Systems Biology 2_1 Genomics, comparative genomics, functional genomics 2_2 Transcriptomics 2_3 Proteomics 2_4 Metabolomics 2_5 Glycomics 2_6 Molecular genetics, reverse genetics and RNAi 2_7 Quantitative genetics 2_8 Epigenetics and gene regulation 2_9 Genetic epidemiology 2_10 Bioinformatics 2_11 Computational biology 2_12 Biostatistics 2_13 Systems biology 2_14 Biological systems analysis, modelling and simulation 3 Cellular and Developmental Biology | | |
|--|------|--|
| 2_2 Transcriptomics 2_3 Proteomics 2_4 Metabolomics 2_5 Glycomics 2_6 Molecular genetics, reverse genetics and RNAi 2_7 Quantitative genetics 2_8 Epigenetics and gene regulation 2_9 Genetic epidemiology 2_10 Bioinformatics 2_11 Computational biology 2_12 Biostatistics 2_13 Systems biology 2_14 Biological systems analysis, modelling and simulation | 2 | Genetics, Genomics, Bioinformatics and Systems Biology |
| 2_3 Proteomics 2_4 Metabolomics 2_5 Glycomics 2_6 Molecular genetics, reverse genetics and RNAi 2_7 Quantitative genetics 2_8 Epigenetics and gene regulation 2_9 Genetic epidemiology 2_10 Bioinformatics 2_11 Computational biology 2_12 Biostatistics 2_13 Systems biology 2_14 Biological systems analysis, modelling and simulation | 2_1 | Genomics, comparative genomics, functional genomics |
| 2_4 Metabolomics 2_5 Glycomics 2_6 Molecular genetics, reverse genetics and RNAi 2_7 Quantitative genetics 2_8 Epigenetics and gene regulation 2_9 Genetic epidemiology 2_10 Bioinformatics 2_11 Computational biology 2_12 Biostatistics 2_13 Systems biology 2_14 Biological systems analysis, modelling and simulation | 2_2 | Transcriptomics |
| 2_5 Glycomics 2_6 Molecular genetics, reverse genetics and RNAi 2_7 Quantitative genetics 2_8 Epigenetics and gene regulation 2_9 Genetic epidemiology 2_10 Bioinformatics 2_11 Computational biology 2_12 Biostatistics 2_13 Systems biology 2_14 Biological systems analysis, modelling and simulation | 2_3 | Proteomics |
| 2_6 Molecular genetics, reverse genetics and RNAi 2_7 Quantitative genetics 2_8 Epigenetics and gene regulation 2_9 Genetic epidemiology 2_10 Bioinformatics 2_11 Computational biology 2_12 Biostatistics 2_13 Systems biology 2_14 Biological systems analysis, modelling and simulation | 2_4 | Metabolomics |
| 2_7 Quantitative genetics 2_8 Epigenetics and gene regulation 2_9 Genetic epidemiology 2_10 Bioinformatics 2_11 Computational biology 2_12 Biostatistics 2_13 Systems biology 2_14 Biological systems analysis, modelling and simulation | 2_5 | Glycomics |
| 2_8 Epigenetics and gene regulation 2_9 Genetic epidemiology 2_10 Bioinformatics 2_11 Computational biology 2_12 Biostatistics 2_13 Systems biology 2_14 Biological systems analysis, modelling and simulation | 2_6 | Molecular genetics, reverse genetics and RNAi |
| 2_9Genetic epidemiology2_10Bioinformatics2_11Computational biology2_12Biostatistics2_13Systems biology2_14Biological systems analysis, modelling and simulation | 2_7 | Quantitative genetics |
| 2_10 Bioinformatics 2_11 Computational biology 2_12 Biostatistics 2_13 Systems biology 2_14 Biological systems analysis, modelling and simulation | 2_8 | Epigenetics and gene regulation |
| 2_11 Computational biology 2_12 Biostatistics 2_13 Systems biology 2_14 Biological systems analysis, modelling and simulation | 2_9 | Genetic epidemiology |
| 2_12 Biostatistics 2_13 Systems biology 2_14 Biological systems analysis, modelling and simulation | 2_10 | Bioinformatics |
| 2_13 Systems biology 2_14 Biological systems analysis, modelling and simulation | 2_11 | Computational biology |
| 2_14 Biological systems analysis, modelling and simulation | 2_12 | Biostatistics |
| | 2_13 | Systems biology |
| 3 Cellular and Developmental Biology | 2_14 | Biological systems analysis, modelling and simulation |
| | 3 | Cellular and Developmental Biology |



| 3_1 | Morphology and functional imaging of cells |
|----------|---|
| 3_2 | Cell biology and molecular transport mechanisms |
| 3_3 | Cell cycle and division |
| 3_4 | Apoptosis |
| 3_5 | Cell differentiation, physiology and dynamics |
| 3_6 | Organelle biology |
| 3_7 | Cell signalling and cellular interactions |
| 3_8 | Signal transduction |
| 3_9 | Development, developmental genetics, pattern formation and embryology |
| 3_10 | Cell genetics |
| 3_11 | Stem cell biology |
| 3_12 | Morphology and functional imaging of cells |
| 4 | Physiology, Pathophysiology and Endocrinology |
| 4_1 | Organ physiology and pathophysiology |
| 4_3 | Endocrinology |
| 4 4 | Ageing |
| 4_5 | Metabolism, biological basis of metabolism related disorders |
| 4_6 | Cancer and its biological basis |
| 4 7 | Cardiovascular diseases |
| 4_8 | Non-communicable diseases (except for neural/psychiatric, immunity-related, metabolism- |
| | related disorders, cancer and cardiovascular diseases) |
| - | Nouvesiances and Nouvel Disardors |
| 5 5_1 | Neurosciences and Neural Disorders Neuroanatomy and neurophysiology |
| 5 2 | Molecular and cellular neuroscience |
| 5_3 | Neurochemistry and neuropharmacology |
| 5_4 | Sensory systems (e.g. visual system, auditory system) |
| 5_5 | Mechanisms of pain |
| 5_6 | Developmental neurobiology |
| 5_7 | Cognition (e.g. learning, memory, emotions, speech) |
| 5_8 | Behavioural neuroscience (e.g. sleep, consciousness, handedness) |
| 5_9 | Systems neuroscience |
| 5_10 | Neuroimaging and computational neuroscience |
| 5_11 | Neurological disorders (e.g. Alzheimer's disease, Huntington's disease, Parkinson's |
| | disease) |
| 5_12 | Psychiatric disorders (e.g. schizophrenia, autism, Tourette's syndrome, obsessive compulsive |
| | disorder, depression, bipolar disorder, attention deficit hyperactivity disorder) |
| 6 | Immunity and Infection |
| 6_1 | Innate immunity and inflammation |
| 6_2 | Adaptive immunity |
| 6_3 | Phagocytosis and cellular immunity |
| 6_4 | Immunosignalling |
| 6_5 | Immunological memory and tolerance |
| 6_6 | Immunogenetics |
| 6_7 | Microbiology |
| 6_8 | Virology |
| 6_9 | Bacteriology |
| 6_10 | Parasitology |
| 6_11 | Prevention and treatment of infection by pathogens (e.g. vaccination, antibiotics, fungicide) |
| 6_12 | Biological basis of immunity related disorders (e.g. autoimmunity) |
| 7 | Diagnostic Tools, Therapies and Public Health |



| 7_1 | Medical engineering and technology |
|------|---|
| 7_2 | Diagnostic tools (e.g. genetic, imaging) |
| 7_3 | Pharmacology, pharmacogenomics, drug discovery and design, drug therapy |
| 7_4 | Analgesia and Surgery |
| 7_5 | Toxicology |
| 7_6 | Gene therapy, cell therapy, regenerative medicine |
| 7_7 | Radiation therapy |
| 7_8 | Health services, health care research |
| 7_9 | Public health and epidemiology |
| 7_10 | Environment and health risks, occupational medicine. |

| 8 | Applied life Sciences and Non-Medical Biotechnology |
|-----|---|
| 8_1 | Applied genetic engineering, transgenic organisms, recombinant proteins, biosensors |
| 8_2 | Synthetic biology, chemical biology and new bio-engineering concepts |
| 8 3 | Food sciences |

Classify your proposal, mandatory.

| Individual proposal |
|---------------------|
| Consortium |

Classify your proposal, mandatory.

| Proposal without Co-Owner(s) of Asset/s |
|---|
| Proposal with Co-Owner(s) of Asset/s |

If user selects Proposal with Co-Owner(s) of Asset/s, then "Co-Owner of Asset/s details" is shown.

INFORMATION FOR "LA CAIXA"

This information will be only used for monitoring/statistical purposes.

Are you or any member of your group applying to any other "la Caixa" Foundation call (research, innovation projects and fellowships, mandatory.


| | Yes | |
|--|-----|--|
| | No | |

If user answers yes to the previous question:

Please indicate the application code (such as HR20-00001, Cl19-00001...) for each of the proposals where you or a member of your group apply:

| # | Application code |
|---|------------------|
| 1 | HR21-00001 |
| 2 | CI21-00001 |
| 3 | CC21-10001 |

Do you or any member of your group have an ongoing project with "la Caixa" Foundation (research, innovation projects and fellowships)? mandatory.



| Yes |
|-----|
| No |


If user answers yes to the previous question:

Please indicate the application code (such as LCF/PR/HR17/52150017) for each of the proposals where you or a member of your group take part.

| # | Application code |
|---|----------------------|
| 1 | LCF/PR/HR17/52150017 |

Select the option that best suits your proposal, mandatory.

| Cardiovascular |
|--|
| Experimental and mathematical sciences |
| Infectious diseases |
| Medical sciences |
| Neurosciences |
| Oncology |
| Other health sciences |



PLEASE CHOOSE THE SCENARIO THAT BETTER MATCHES THE CURRENT STATUS OF YOUR PROJECT.

SCENARIO 1:

- 1. A Proof of Concept experiment has not been carried out yet.
- **2.** The Intellectual Property strategy is still not defined or it is unclear.
- 3. The team expertise is mainly scientific.
- 4. The requested funding will be mainly used for proving that your idea may be a good solution for the need it intends to address.
- 5. According to the Technology Readiness Levels (TRL), your project will be marked as TRL 1-2.


SCENARIO 2:


- 1. Initial *Proof of Concept* experiments that led to the definition of the Asset/s have been carried out.
- 2. The Intellectual Property strategy of the Asset/s is defined.
- 3. The value proposition for the Asset/s is defined.
- 4. The team expertise is mainly scientific, but some tech transfer profiles may be incorporated.
- 5. The requested funding will be used to advance on the scientific and/or technical development of the Asset/s, but activities focused on legal, business, and commercial aspects may also be performed.
- 6. The team has identified who the clients and end-users of the Asset/s are, and envision how the Asset/s will generate revenues.
- 7. According to the Technology Readiness Levels (TRL), your project will be marked as TRL 3-4.

SCENARIO 3:

- 1. The team has carried out a relevant *Proof of Concept* of the Asset/s in relevant models or test environments.
- **2.** The Intellectual Property strategy is defined and it is being implemented.
- 3. There are some tech transfer profiles engaged in the project.
- 4. The value proposition of the Asset/s is defined.
- 5. The requested funding will be used to advance on the scientific and/or technical development of the Asset/s, but activities focused on legal, business, and commercial aspects will be performed as well.
- **6. The team has procured partnerships with** *prospective licensees and/or private investors*.
- 7. The team has a plan to meet the regulatory requirements the Asset/s should abide by.
- 8. The team has identified risks ahead on the route towards the market and have a plan to overcome them.
- 9. The team has identified who the clients and end-users of the Asset/s are, and envision how the Asset/s will generate revenues.
- **10.** The team has performed a deep analysis on the market and competitors.
- 11. The exploitation plan for the Asset/s is outlined.
- 12. According to the Technology Readiness Levels (TRL), your project will be marked as TRL 4 or higher.

Scenario 1 /Scenario 2 /Scenario 3. Mandatory





PROPOSAL ABSTRACT

The abstract must provide a brief description of the project, the specific objectives and the values that it brings to its scientific field and society. 2000 characters. Mandatory.

LAY SUMMARY

Briefly summarize the project, including a description of the Asset, for a non-expert audience. 1000 characters. Mandatory.

Stage 1

Block 1 – Asset

BRIEF DESCRIPTION OF YOUR ASSET/S

Describe your Asset/s. 500 Characters. Mandatory.

SCIENTIFIC RATIONALE

» Explain the scientific excellence and originality of the Asset/s in the context of the state-ofthe-art. 1000 characters. Mandatory.

FIVE MOST IMPORTANT SCIENTIFIC PUBLICATIONS

» Up to 5 references. Optional.

| # | DOI | Title of the document | Authors | Journal | Year |
|---|-----|-----------------------|---------|---------|------|
| | | | | | |

SUPPORTING DATA

» Describe the preliminary data that supports the hypothesis and the scientific approach of your idea. 2000 characters. Mandatory.

SUPPORTING EXPERIMENTAL/TECHNICAL FIGURES OR PROTOTYPES

» Only one PDF of maximum 2 Pages. Optional.


Block 2 – Need

NEED OR PROBLEM TO BE SOLVED

Description of the unmet clinical needs you envision the Asset/s may cover.

2500 characters. Mandatory.





Block 3 - Team

PROJECT LEADER'S EXPERIENCE AND EXPERTISE

Describe the capabilities of the project leader that would contribute to the development of the Asset/s. Describe the future involvement in the project beyond this program.

1500 characters. Mandatory.

COMPLEMENTARY OF THE TEAM MEMBERS

» Provide details of the team members' profile, previous experience, and dedication and commitment to the project. Describe how they are relevant and complementary for its successful execution. 1500 characters. Mandatory.

TEAM MEMBERS TABLE

| Initials full | Job title, centre | Email | Profile, | Dedication |
|---------------|-------------------|-----------------|------------------|-----------------|
| name | | | experience | |
| 6 characters. | 100 characters | 100 characters. | 1000 characters. | 1000 characters |

LETTERS OF SUPPORT OR RECOMMENDATION

» One PDF up to 5 MB. Optional

Block 4 – Implementation

PROJECT MILESTONES

Describe the specific milestones for the next two years. 1000 characters. Mandatory

ACTIVITIES TO BE PERFORMED

» Please describe all activities estimated to be developed for the next two years and indicative cost according to table provided under "Budget" section. All the actions should be linked to specific project milestones.

2500 characters. Mandatory.

BUDGET

See Annex I

Block 5 –Business Case and social impact

TRANSFORMATION EXPECTATIONS FOR SOCIETY

» Describe the potential contribution of the Asset/s in improving people's quality of life, social progress, and human development. **2000 characters. Mandatory.**



Stage 2

Block 1 – Asset

BRIEF DESCRIPTION OF YOUR ASSET/S.

Describe your Asset/s. 500 Characters. Mandatory.

SCIENTIFIC RATIONALE

» Explain the scientific excellence and originality of the Asset/s in the context of the state-ofthe-art. 1000 characters. Mandatory.

FIVE MOST IMPORTANT SCIENTIFIC PUBLICATIONS

» Up to 5 references. Optional.

| # | DOI | Title of the document | Authors | Journal | Year |
|---|-----|-----------------------|---------|---------|------|
| | | | | | |

SUPPORTING DATA

» Describe the preliminary data that supports the hypothesis and the scientific approach of your idea. 2000 characters. Mandatory.

SUPPORTING EXPERIMENTAL/TECHNICAL FIGURES OR PROTOTYPES

» Only one PDF of maximum 2 Pages. Optional.

DO YOU HAVE AN INTELLECTUAL PROPERTY RIGHTS STRATEGY IN PLACE? (THIS MEANS ANY FILED PATENT OR UTILITY MODEL, TRADEMARK, INDUSTRIAL DESIGN RIGHT OR TRADE SECRET).


» Yes/No. Mandatory

If user answers yes to the previous yes/no question:

WHICH IPR STATUS MATCHES BETTER YOUR ASSET/S

» Please indicate the Protection status of the Asset/s. Mandatory

| Patent pending |
|-------------------------|
| Utility model pending |
| Patent granted |
| Utility model granted |
| Trademark |
| Industrial design right |
| Trade Secret |
| Copyright |



BRIEFLY DESCRIBE WHAT EXACTLY IS PROTECTED.

» Which is claimed in your patent/utility model/industrial design/trademark or protected by trade secret? Please also add the regions and time scope in which your Asset/s is protected. Please, also provide any other information that may support your IPR position (e.g., ISR, EESR, or Freedom to Operate Analysis). Also, please, add information about any future actions about IPR in the future. 2000 characters. Mandatory.

RELEVANT PATENT OR UTILITY MODEL DOCUMENTS.

» One PDF up to 5 MB. Optional

If user answers no to the previous yes/no question:

WHAT IP PROTECTION STRATEGY DO YOU PLAN TO FOLLOW? PLEASE PROVIDE ANY INFORMATION SUPPORTING IT.

» How do you plan to protect your Asset/s to support its exploitation? Why do you think this would be the best option to protect your Asset/s? Mandatory, 1500 characters.

Block 2 – Need

NEED OR PROBLEM TO BE SOLVED

» Description of the reasons behind the development of the Asset/s. Describe the unmet need or problem it addresses and the foreseen impact after its implementation. 2500 characters. Mandatory.

POTENTIAL OF YOUR ASSET/S TO BE USED FOR OTHER UNMET NEEDS

» Briefly describe other possible indications you envision your idea may be used for. 1000 characters. Mandatory.

VALUE PROPOSITION

» Describe whether the product represents a novelty compared to the current solutions. 2000 characters. Mandatory.

IDENTIFICATION AND INVOLVEMENT OF THE DIFFERENT STAKEHOLDERS


» Which people or groups of people are critical for the success of the project and could therefore have a positive or negative effect on the transfer to the market? (patient as., clients, endusers, beneficiaries, prescriptors, etc...) 2000 characters. Mandatory.

Block 3 – Team

PROJECT LEADER'S EXPERIENCE AND EXPERTISE

» Describe the capabilities of the project leader that would contribute to the development of the Asset/s. Describe the future involvement in the project beyond this program. 1500 characters. Mandatory.





COMPLEMENTARY OF THE TEAM MEMBERS

» Provide details of the team members' profile, previous experience, and dedication and commitment to the project. Describe how they are relevant and complementary for its successful execution. 1500 characters. Mandatory.

PROJECT LEADER'S AND TEAM'S EXPERIENCE IN TECH TRANSFER AND INNOVATION.

» Describe the project leader's and team member's level of knowledge in the fields of business management, technology transfer, and innovation management. 1500 characters. Mandatory.

TEAM MEMBERS TABLE

| Initials full name | Job title, centre | Email | Profile, experience | Dedication |
|--------------------|-------------------|-----------------|---------------------|-----------------|
| 6 characters. | 100 characters | 100 characters. | 1000 characters. | 1000 characters |

LETTERS OF SUPPORT OR RECOMMENDATION

» One PDF up to 5 MB. Optional

Block 4- Implementation

PROJECT MILESTONES

» Describe the specific milestones for the next two years. Please explain how these objectives relate to the complete Roadmap of Asset/s development until commercialisation. 1000 characters. Mandatory.

ACTIVITIES TO BE PERFORMED

» Please, describe all activities to be developed for the next two years and indicative cost according to table provided under "Budget" section. All the actions should be linked to specific project milestones. 2500 characters. Mandatory.

WORK PLAN (GANTT CHART)

- » Please indicate the proposal workplan in a Gantt Diagram. Use the + button below to add Tasks. They will be displayed in the Gantt Chart below, after doing save draft.
- » To enter each Gantt task, the user should enter a Task Name, a Start Date, an End Date and a Description of no more than 500 characters. Mandatory.


OTHER SUPPORT

» Description of support (financial/non-financial) received from other collaborations/programs to implement actions in the Development Roadmap. Discuss prospective support or collaborations that you have already procured. 1000 characters. Mandatory.

BUDGET

» See Annex I





Block 5 – Business case and social impact

TRANSFORMATION EXPECTATIONS FOR SOCIETY

» Describe the potential contribution of the Asset/s in improving people's quality of life, social progress, and human development. 2000 characters. Mandatory.

HOW DO YOU ENVISION THAT YOUR ASSET/S WOULD BE ATTRACTIVE FOR THE MARKET?

» How do you envision that your Asset/s will produce revenues and be sustainable in the long term? Who will pay for it (client)? 2000 characters. Mandatory.

Stage 3

Block 1 – Asset

BRIEF DESCRIPTION OF YOUR ASSET/S.

» Describe your Asset/s. 500 Characters. Mandatory.

SCIENTIFIC RATIONALE

» Explain the scientific excellence and originality of the Asset/s in the context of the state-ofthe-art. 1000 characters. Mandatory.

FIVE MOST IMPORTANT SCIENTIFIC PUBLICATIONS

» Up to 5 references. Optional.

| # | DOI | Title of the document | Authors | Journal | Year |
|---|-----|-----------------------|---------|---------|------|
| | | | | | |

SUPPORTING DATA

» Describe the preliminary data that supports the hypothesis and the scientific approach of your idea. Mandatory. 2000 characters.

SUPPORTING EXPERIMENTAL/TECHNICAL FIGURES OR PROTOTYPES

» Only one PDF of maximum 2 Pages. Optional.


DO YOU HAVE AN INTELLECTUAL PROPERTY RIGHTS STRATEGY IN PLACE? (THIS MEANS ANY FILED PATENT OR UTILITY MODEL, TRADEMARK, INDUSTRIAL DESIGN RIGHT OR TRADE SECRET).

» Yes/No. Mandatory

If the user answers yes to the previous yes/no question:

WHICH IPR STATUS MATCHES BETTER YOUR ASSET/S

» Please indicate the Protection status of the Asset/s. Mandatory



| Patent pending |
|-------------------------|
| Utility model pending |
| Patent granted |
| Utility model granted |
| Trademark |
| Industrial design right |
| Trade Secret |
| Copyright |

BRIEFLY DESCRIBE WHAT EXACTLY IS PROTECTED.

» Which is claimed in your patent/utility model/industrial design/trademark or protected by trade secret? Please, also add the regions and time scope in which your Asset/s is protected. Please, also provide any other information that may support your IPR position (e.g., ISR, EESR, or Freedom to Operate Analysis). Also, please, add information about any future actions about IPR in the future. **Mandatory. 2000 characters.**

RELEVANT PATENT OR UTILITY MODEL DOCUMENTS.

» One PDF up to 5 MB. Optional

If user answers no to the previous yes/no question:

WHAT IP PROTECTION STRATEGY DO YOU PLAN TO FOLLOW? PLEASE PROVIDE ANY INFORMATION SUPPORTING IT.

» How do you plan to protect your Asset/s to support its exploitation? Why do you think this would be the best option to protect your Asset/s? **Mandatory. 1500 characters.**

Block 2 – Need

NEED OR PROBLEM TO BE SOLVED

» Description of the reasons behind the development of the Asset/s. Describe the unmet need or problem it addresses and the foreseen impact after its implementation. **2500 characters. Mandatory.**

POTENTIAL OF YOUR ASSET/S TO BE USED FOR OTHER UNMET NEEDS


» Briefly describe other possible indications you envision your idea may be used for. 1000 characters. Mandatory.

VALUE PROPOSITION

» Describe whether the product represents a novelty compared to the current solutions. **2000 characters. Mandatory.**

IDENTIFICATION AND INVOLVEMENT OF THE DIFFERENT STAKEHOLDERS

» Which people or groups of people are critical for the success of the project and could therefore have a positive or negative effect on the transfer to the market? (patient associations, clients, end-users, beneficiaries, prescriptors, etc...) 2000 characters. Mandatory.



Block 3- Team

PROJECT LEADER'S EXPERIENCE AND EXPERTISE

» Describe the capabilities of the project leader that would contribute to the development of the Asset/s. Describe the future involvement in the project beyond this program. **1500 characters. Mandatory.**

COMPLEMENTARY OF THE TEAM MEMBERS

» Provide details of the team members' profile, previous experience, and dedication and commitment to the project. Describe how they are relevant and complementary for its successful execution. 1500 characters. Mandatory.

PROJECT LEADER'S AND TEAM'S EXPERIENCE IN TECH TRANSFER AND INNOVATION

 Describe the project leader's and team members' level of knowledge in the fields of business management, technology transfer, and innovation management.
 1500 characters. Mandatory.

SKILLS GAP ANALYSIS

» Identify the skills envisaged to be acquired in order to advance the project and how you plan to attract them (e.g., recruiting, training team members, outsourcing). 1500 characters. Mandatory.

TEAM MEMBERS TABLE

| Initials full name | Job title, centre | Email | Profile, experience | Dedication |
|--------------------|-------------------|-----------------|---------------------|-----------------|
| 6 characters. | 100 characters | 100 characters. | 1000 characters. | 1000 characters |

Block 4 – Implementation

PROJECT MILESTONES


» Describe the specific milestones for the next two years. Please explain how these objectives relate to the complete Roadmap of Asset/s development until commercialisation. 1000 characters. Mandatory.


ACTIVITIES TO BE PERFORMED

» Please describe all activities to be developed for the next two years and indicative cost according to table provided under "Budget" section. All the actions should be linked to specific project milestones. **2500 characters. Mandatory.**

WORK PLAN (GANTT CHART)

- » Please indicate the proposal workplan in a Gantt Diagram. Use the + button below to add Tasks. They will be displayed in the Gantt Chart below, after doing save draft.
- » To enter each Gantt task, the user should enter a Task Name, a Start Date, an End Date and a Description of no more than 500 characters. **Mandatory.**





RISK ANALYSIS

» Please describe the type of risk your project will face (technological, commercial, financial, etc...), explain how likely these risks will appear and how you plan to overcome them. 1500 characters. Mandatory.

OTHER SUPPORT

» Description the support (financial/non-financial) received other collaborations/programs to implement actions in the Development Roadmap. Discuss prospective support or collaborations that you have already procured. 1000 characters. Mandatory.

NON-FINANCIAL SUPPORT NEEDED

» Detail the specific non-financial support that is foreseen in this stage of the project. 1000 characters. Mandatory.

REGULATORY ROADMAP

» Explain the regulatory requirements to be fulfilled for the exploitation of the Asset/s and how they are to be met. 1500 characters. Mandatory.

BUDGET

» See Annex I

Block 5 – Business case and social impact

TRANSFORMATION EXPECTATIONS FOR SOCIETY

» Describe the potential contribution of the Asset/s in improving people's quality of life, social progress, and human development. 2000 characters. Mandatory.

HOW DO YOU ENVISION THAT YOUR ASSET/S WOULD BE ATTRACTIVE FOR THE MARKET?

» How do you envision that your Asset/s will produce revenues and be sustainable in the long term? Who will pay for it (client)? 2000 characters. Mandatory.

EXPLOITATION STRATEGY

» Describe your exploitation plan as well as the key steps to reach the market. Indicate possible collaborations with third parties for making a successful commercial exploitation. Explain the main market barriers and how you plan to overcome them. You can add a full business plan as an attachment (optional). 2000 characters. Mandatory.


MARKET ANALYSIS AND COMPETITORS

» Indicate the most relevant market segments to reach and possible collaboration with third parties for making a successful commercial exploitation. Analyze the competing approaches in the field. Estimation of the potential market size. 2000 characters. Mandatory.

BUSINESS PLAN

One PDF up to 5MB





Annex I. Budget Table

| | Amount Requested by the beneficiary | Amount requested by partner (1,,4) * | Other Contributions | Comments** |
|--|-------------------------------------|--------------------------------------|------------------------|------------|
| Total | | | | |
| Materials for experiments / R&D | | | | |
| Outsourcing of activities for R&D | | | | |
| development | | | | |
| Personnel for the project | | | | |
| Intellectual property protection | | | | |
| Technical/scientific advice | | | | |
| Business advice | | | | |
| Legal advice | | | | |
| Market analysis | | | | |
| Regulatory development | | | | |
| Production and Quality | | | | |
| Design | | | | |
| Prototyping | | | | |
| Travel expenses related to the project | | | | |
| Others | | | | |
| Overheads*** | | | | |
| Commercial and Business Development | | | | |
| actions | | | | |

NOTES:

Maximum budget is €50,000 for Stage 1, €150,000 for Stage 2, and €500,000 for Stage 3.

^{*}One column (up to 4) will appear per invited partner (if any).

^{**}Comments are compulsory for every line in which money is allocated, with a maximum of 500 characters per line

^{***}Overheads are only eligible up to a 10% of the total budget in Stage 2 and Stage 3 applications.